Meeting
2016 ASCO Annual Meeting
Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.
Authors
Pedro Nazareth Aguiar
Federal University of Sao Paulo, Sao Paulo, Brazil
Pedro Nazareth Aguiar , Hakaru Tadokoro , CARMELIA MARIA NOIA BARRETO , Ilka Lopes Santoro , Ramon Andrade De Mello , Hani M. Babiker , Kiran Avancha , Gilberto Lopes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9033)
DOI
10.1200/JCO.2016.34.15_suppl.9033
Abstract #
9033
Poster Bd #
356
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
The impact of PD-L1 on survival and values of nivolumab, atezolizumab, and pembrolizumab compared with docetaxel in second-line non-small cell lung cancer.
First Author: Helmy M. Guirgis
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
First Author: Sun Young Jeong
Poster
2022 ASCO Annual Meeting
Monitoring PD-L1 expression on circulating stromal cells in blood predicts PFS and OS in patients with metastatic NSCLC treated with PD-L1/PD-1 immunotherapy.
First Author: Jillian Moran
Poster
2020 ASCO Virtual Scientific Program
ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
First Author: Jacob Sands